Annovis Bio (ANVS) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
INmune Bio (INMB) has outperformed Annovis Bio (ANVS) over the past year, losing 9.0% versus a loss of 48.5%. Over five years, INMB leads with a -90.2% price change compared with -95.8% for ANVS. INmune Bio is the larger company by market cap ($50.8 million vs $49.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | INMB |
|---|---|---|
| Share price | $1.17 | $1.83 |
| Market cap | $49.93M | $50.79M |
| 1-day change | -3.31% | -1.61% |
| YTD return | -66.18% | +17.31% |
| 1-year return | -48.46% | -8.96% |
| 5-year return | -95.82% | -90.17% |
| EPS (TTM) | $-1.75 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $2.60 |
| 52-week low | $1.04 | $1.09 |
| Distance from 52-week high | -78.73% | -29.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +797.44% | +282.51% |
| Average volume | 884.63K | 402.12K |
| Shares outstanding | 42.68M | 27.75M |
| Employees | 7 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed ANVS by 39.5 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
ANVS vs INMB FAQ
Which is bigger, Annovis Bio or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $50.79M compared with $49.93M for Annovis Bio (ANVS).
Which stock has performed better over the past year, ANVS or INMB?
INMB returned -8.96% over the past 12 months, compared with -48.46% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and INmune Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Annovis Bio and Biotechnology: Biological Products (No Diagnostic Substances) for INmune Bio.